<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675870</url>
  </required_header>
  <id_info>
    <org_study_id>195183-202</org_study_id>
    <nct_id>NCT00675870</nct_id>
  </id_info>
  <brief_title>Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia</brief_title>
  <official_title>Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NRX 195183 is effective in the treatment of&#xD;
      relapsed or refractory Acute Promyelocytic Leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common current therapeutic approach to APL uses oral ATRA and chemotherapy in induction and&#xD;
      consolidation. This approach has significantly improved survival in newly diagnosed APL&#xD;
      patients. However, approximately 30% of patients relapse. Recently, an approach involving the&#xD;
      combination of oral ATRA and arsenic trioxide has been tested. The prognosis for relapsed&#xD;
      patients is very poor. This study seeks to investigate NRX 195183 monotherapy in patients who&#xD;
      have failed or are resistant to or are intolerant of any prior therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Complete Remission</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRX 195183 Soft Gelatin Capsule</intervention_name>
    <description>Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of APL morphology or FAB M3 variant confirmed by RT-PCR assay or&#xD;
             chromosome analysis/FISH showing t(15:17) translocation. Patients must also have&#xD;
             relapse from, resistance to or intolerance of any one or more of the following&#xD;
             therapies:&#xD;
&#xD;
               -  ATRA&#xD;
&#xD;
               -  Cytotoxic chemotherapy&#xD;
&#xD;
               -  Arsenic trioxide&#xD;
&#xD;
          -  Patients must be 18 or older.&#xD;
&#xD;
          -  Bilirubin equal or less than 1.5 times the upper limit of normal.&#xD;
&#xD;
          -  Creatinine equal or less than 1.5 times the upper limit of normal.&#xD;
&#xD;
          -  Patients entered into this study should be non-pregnant and non-nursing and should not&#xD;
             plan on becoming pregnant while on treatment. Treatment under this protocol would&#xD;
             expose an unborn child to significant risks. Women and men of reproductive potential&#xD;
             should agree to use an effective means of birth control. There is an extremely high&#xD;
             risk that a severely deformed infant will result if NRX 195183 is administered during&#xD;
             pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-APL, AML patients should be excluded from the study.&#xD;
&#xD;
          -  Other serious illnesses which would limit survival to 6 months.&#xD;
&#xD;
          -  Psychiatric conditions which would prevent compliance with treatment or informed&#xD;
             consent.&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease. This would include history of a recent&#xD;
             acute myocardial infarction, uncontrolled congestive heart failure, or active angina.&#xD;
&#xD;
          -  AIDS or HIV positive patients, although HIV test is not required for accrual.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nonna Snider, BS/BA</last_name>
    <phone>949-336-7111</phone>
    <email>nsnider@nurxpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Gero</last_name>
    <phone>949-336-7111</phone>
    <email>lgero@nurxpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica,</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Chua</last_name>
      <phone>310-552-9999</phone>
      <email>vikychua@aol.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <last_update_submitted>May 9, 2008</last_update_submitted>
  <last_update_submitted_qc>May 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Roshantha A. Chandraratna, PhD, MBA, Chief Scientific Officer</name_title>
    <organization>NuRx Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Acute Promyelocytic Leukemia</keyword>
  <keyword>Cancer</keyword>
  <keyword>Leukemia</keyword>
  <keyword>APL</keyword>
  <keyword>ATRA</keyword>
  <keyword>Tretinoid</keyword>
  <keyword>Vesanoid</keyword>
  <keyword>Retinoic Acid Receptor Alpha</keyword>
  <keyword>All Trans Retinoic Acid</keyword>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>Trisenox</keyword>
  <keyword>Retinoid</keyword>
  <keyword>Relapsed or Refractory Acute Promyelocytic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

